Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Crystal financial tombstone celebrating the initial public offering of Emcure Pharmacuticals on the Bombay Stock Exchange and National Stock Exchange. The Pune, India-based drugmaker focuses on women’s healthcare. (24AKL301)
Crystal deal toy, featuring 3D laser etching, commemorating a private placement by Nordic Nanovector. The Norwegian life sciences firm develops drugs for the treatment of cancer.
(9LJW269)Crystal deal toy celebrating the initial public offering by pharmaceutical firm Rua Bioscience. The New Zealand-based company is licensed to produce cannabis-derived medicines.
(20ALJ334)Lucite tombstone celebrating Series B financing for Texas-based biotech firm OncoNano Medicine.
(21ALJ040)Crystal deal toy, featuring a 3D laser-etch of lungs, commemorating a drug commercialization agreement in Japan. The collaboaration between biotherapeutics firm aTyr Pharma and Kyorin Pharmaceutical centers on a treatment for lung diseases.
(20ALJ110)Crystal deal toy commemorating a follow-on offering by electroCore, a bioelectronic medicine company.
(21AJH117)Lucite commemorative celebrating a development and commercialization agreement between Takeda and Arrowhead Pharmaceuticals.
(21ALJ357)Custom crystal celebrating the submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA). The application, related to Impel NeuroPharma’s migraine treatment INP104, was supported by a Phase 3, open-label STOP-301 Trial.
(20ALJ356)Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
"*" indicates required fields
